Status:
RECRUITING
An Integrated Radio-immunological Approach
Lead Sponsor:
Istituto Oncologico Veneto IRCCS
Collaborating Sponsors:
Azienda Ospedaliero-Universitaria Careggi
Azienda Ospedaliera di Padova
Conditions:
Glioma, Malignant
Eligibility:
All Genders
18-80 years
Brief Summary
The most aggressive primary brain tumors in adults, glioblastomas, are characterized by a profound local and systemic immune suppression. During tumor progression, the infiltration of inflammatory leu...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- All patients with histologic confirmation of malignant glioma
- Patients must be age \>= 18 years
- Patients must be able to obtain an MRI scan with gadolinium contrast
- Patients must sign informed consent indicating that they are aware of the investigational nature of this study:
Exclusion
Key Trial Info
Start Date :
February 23 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2025
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT05267509
Start Date
February 23 2022
End Date
June 30 2025
Last Update
March 11 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital
Florence, Italy
2
University Hospital
Padua, Italy, 325128